Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2000-2005

  Hirata, Koichi ^a   Horikoshi, Noboru ^b   Aiba, Keisuke ^b   Okazaki, Minoru ^a   Denno, Ryuichi ^a   Sasaki, Kazuaki ^a   Nakano, Yasuyuki ^b   Ishizuka, Hikaru ^b   Yamada, Yasuhide ^b   Uno, Shinji ^b   Taguchi, Tetsuo ^c   Shirasaka, Tetsuhiko ^d  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c Japan Soc for Cancer Chemotherapy   (Japan)

^d TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OXONATE POTASSIUM; PRODRUG; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE CALCULATION; DRUG ACCUMULATION; DRUG DETERMINATION; DRUG MECHANISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DRUG COMBINATIONS; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OXONIC ACID; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR;

EID: 6544263262     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Heidelberger, C., Chaudhuri, N. K., Danneberg, P., Mooren, D., Griesbach, L., Duschinsky, R., Schnitzer, R. J., Pleven, E., and Scheiner, J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature (Lond.), 179: 663-666, 1957.
2. Pinedo, H. M., and Peters, G. F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., 6: 1653-1664, 1988.
3. Vogelzang, N. J. Continuous infusion chemotherapy: a critical review. J. Clin. Oncol., 2: 1289-1304, 1984.
4. Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., and Fryer, J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J. Clin. Oncol., 7: 425-432, 1989.
5. The meta-analysis group in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol., 16: 301-308, 1998.
6. Yoshida, T., Araki, E., Iigo, M., Fujii, T., Yoshino, M., Shimada, Y., Saito, D., Tajiri, H., Yamaguchi, H., Yoshida, S., Yoshino, M., Ohkura, H., Yoshimori, M., and Okazaki, N. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer. Cancer Chemother. Pharmacol., 26: 352-354, 1990.
7. Trump, D. L., Egorin, M. J., Forrest, A., Willson, J. K. V., Remick, S., and Tutsch, K. D. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J. Clin. Oncol., 9: 2027-2035, 1991.
8. Findlay, M. P. N., Raynaud, F., Cunningham, D., Iveson, A., Collins, D. J., and Leach, M. O. Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-α. Ann. Oncol., 7: 47-53, 1996.
9. Heggie, G. D., Sommadossi, J., Cross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharamacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
10. Harris, B. E., Song, R., Soong, S., and Diasio, R. B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res., 50: 197-201, 1990.
11. Zhang, R., Lu, Z., Liu, T., Soong, S., and Diasio, R. B. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Cancer Res., 53: 2816-2822, 1993.
12. Beck, A., Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Renee, N., and G. Milano. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur. J. Cancer, 30A: 1517-1522, 1994.
13. Houghton, J. A., Houghton, P. J., and Wooten, R. S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res., 39: 2406-2413, 1979.
14. 1-(2′-tetrahydrofuryl)-5-fluorouracil (FT-207). Gan No Rinsho, 17: 731-742, 1971.
15. Ota, K., Taguchi, T., and Kimura, K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother. Pharmacol., 22: 333-338, 1988.
16. Ota, K. Multicentre cooperative phase II study of 5′-deoxy-5-fluorouridine in the treatment of colorectal cancer. J. Int. Med. Res., 16 (Suppl. 2): 19B-20B, 1988.
17. Pazdur, R., Lassere, Y., Rhodes, V., Ajani, J. A., Sugarman, S. M., Patt, Y. Z., Jones D. V., Jr., Markowitz, A. B., Abbruzzese, J. L., Bready, B., and Levin, B. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994.
18. Findlay, M., Cutsem, E. V., Kocha, W., Allman, D., Laffranchi, B., Griffin, T., Osterwalder B., Dalley D., Pazdur R., and Verweij, J. A randomised Phase II study of Xeloda™ (capecitabine) in patients with advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol., 16: 798, 1997.
19. DeMario, M. D., and Ratain, M. J. Oral chemotherapy: rationale and future directions. J. Clin. Oncol., 16: 2557-2567, 1998.
20. Meropol, N. J. Oral fluoropyrimidines in the treatment of colorectal cancer. Eur. J. Cancer, 34: 1509-1513, 1998.
21. Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saito, H., Okabe, H., Oyama, K., Takeda, S., Unemi, N., and Fukushima, M. Antitumor activity of 1 M Tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res., 56: 2602-2606, 1996.
22. Shirasaka, T., Shimamoto, S., Ohsimo, H., Yamaguchi, M., Kato, T., Yonekura, K., and Fukushima, M. Development of a novel from of an oral 5-fluorouracil derivative (S-1) directed to the epotentiation tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs, 7: 548-557, 1996.
23. Takechi, T., Nakano, K., Uchida, J., Mita, A., Toko, K., Takeda, S., Unemi, N., and Shirasaka, T. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother. Pharmacol., 39: 205-211, 1997.
24. Tatsumi, K., Fukushima, M., Shirasaka, T., and Fujii S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn. J. Cancer Res. (Gann), 78: 748-755, 1987.
25. Shirasaka, T., Shimamoto, Y., and Fukushima, M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss, of its antitumor activity in rats. Cancer Res., 53: 4004-4009, 1993.
26. Taguchi, T., Inuyama, Y., Kanamaru, R., Hasegawa, K., Akazawa, S., Niitani, H., Furue, H., Kurihara, M., Ota, K., Suga, S., Ariyoshi, Y., Takai, S., Shimoyama, T., Tohge, T., Takashima, S., Sugimachi, K., Hara, Y., Fujita, H., Kimura, K., Saito, T., Tsukagoshi, S., and Nakao, I. Phase I study of S-1. Jpn. J. Cancer Chemother., 24: 2253-2264, 1997.
27. Horikoshi, N., Mitachi, Y., Sakata, Y., Sugimachi, K., and Taguchi, T. S-1, new oral fluoropyrimidine is very active in patients with advanced gastric cancer (early Phase II study). Proc. Am. Soc. Clin. Oncol., 15: 466, 1996.
28. Matsushima, E., Yoshida, K., Kitamura, R., and Yoshida, K. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry. J. Chromatogr. B., 691: 95-104, 1997.
29. Yamaoka, K., and Tanigawara, Y. The guide of pharmacokinetics by microcomputer, pp. 159-178. Tokyo: Nankoudou, 1983.
30. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA, 87: 492-496, 1990.
31. Hillcoat, B. L., Mcculloch, P. B., Figueredo, A. T., Ehsan, M. H., and Rosenfeld, J. M. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br. J. Cancer, 38: 719-724, 1978.
32. Van Groeningen, C. J., Pinedo, H. M., Heddrs, J., Kok, R. M., De Jong, A. P. J. M., Wattel, E., Peters, G. J., and Lankelma, J. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res., 48: 6956-6961, 1988.
33. Au, J. L., Rustum, Y. M., Ledesma, E. J., Mittelman, A., and Creaven, P. J. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res., 42: 2930-2937, 1982.
34. 1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin. Cancer Res., 4: 2085-2088, 1998.
35. Baker, S. D., Khor, S. P., Adjei, A. A., Doucette, M. Spector, T., Donehower, R. C., Grochow, L. B., Sartorius, S. E., Noe, D. A., Hohneker, J. A., and Rowinsky, E. K. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol., 14: 3085-3096, 1996.
36. Schilsky, R. L., Hohneker, J., Ratain, M. J., Janisch, L., Smetzer, L., Lucas, V. S., Khor, S. P., Diasio, R., Hoff, D. D. V., and Burris, H. A., III. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J. Clin. Oncol., 16: 1450-1457, 1998.
37. Nakajima O., Ihara K., Isoda T., Matsumoto J., Komoda M., Imamura, Y., Koyama Y., and Kimura, T. Phase I/II study of combined 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil (UFT). Jpn. J. Cancer Chemother., 7: 1558-1568, 1980.